Skip to content

INTELLIPHARMACEUTICS INTERNATIONAL INC.: 20-F filed 2012-05-11

What INTELLIPHARMACEUTICS INTERNATIONAL INC. reported in its annual report (foreign private issuer) filed 2012-05-11 (fiscal FY 2011): 28 published measures, 73 facts as tagged in accession 0001171843-12-001847.

This filing

Form
20-F (annual report (foreign private issuer))
Filed
2012-05-11
Fiscal period
fiscal FY 2011
Accession
0001171843-12-001847 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All INTELLIPHARMACEUTICS INTERNATIONAL INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2011-11-306,247,228USD
At 2010-11-303,267,706USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2011-11-309,340,258USD
At 2010-11-303,174,750USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2011-11-30-3,093,030USD
At 2010-11-3092,956USD
At 2009-11-304,632,014USD
At 2008-12-31-583,075USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2011-11-304,817,088USD
At 2010-11-30789,136USD
At 2009-11-308,014,492USD
At 2008-12-31902,213USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2010-12-01 to 2011-11-30-4,880,277USD365
2009-12-01 to 2010-11-30-5,761,091USD365
2009-01-01 to 2009-11-30-1,838,735USD334

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2010-12-01 to 2011-11-30-6,981,448USD365
2009-12-01 to 2010-11-30-6,194,195USD365
2009-01-01 to 2009-11-30-4,857,983USD334

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2010-12-01 to 2011-11-30262,142USD365
2009-12-01 to 2010-11-30133,878USD365
2009-01-01 to 2009-11-3093,412USD334

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2010-12-01 to 2011-11-30501,814USD365
2009-12-01 to 2010-11-301,459,385USD365
2009-01-01 to 2009-11-30630,179USD334

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2010-12-01 to 2011-11-3011,269,162USD365
2009-12-01 to 2010-11-30-907,001USD365
2009-01-01 to 2009-11-30798,496USD334

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2010-12-01 to 2011-11-30-262,142USD365
2009-12-01 to 2010-11-30-133,878USD365
2009-01-01 to 2009-11-3011,241,443USD334

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2011-11-30-23,947,819USD
At 2010-11-30-19,067,542USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2011-11-30951,914USD
At 2010-11-30925,554USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2010-12-01 to 2011-11-30702,461USD365
2009-12-01 to 2010-11-301,023,626USD365
2009-01-01 to 2009-11-3018,529USD334

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2011-11-305,295,314USD
At 2010-11-302,117,479USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2010-12-01 to 2011-11-3083,473USD365
2009-12-01 to 2010-11-3098,435USD365
2009-01-01 to 2009-11-3087,940USD334

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2011-11-302,526,946USD
At 2010-11-303,158,684USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2011-11-30554,210USD
At 2010-11-30612,957USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2011-11-303,383USD
At 2010-11-301,619USD

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2010-12-01 to 2011-11-302,925,454USD365
2009-12-01 to 2010-11-302,699,204USD365
2009-01-01 to 2009-11-30975,197USD334

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2010-12-01 to 2011-11-305,125,608USD365
2009-12-01 to 2010-11-304,533,310USD365
2009-01-01 to 2009-11-301,937,456USD334

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2011-11-3015,908,444shares
At 2010-11-3010,907,054shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2011-11-3020,822,672USD
At 2010-11-3019,369,005USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2011-11-30-115,035USD
At 2010-11-30-225,476USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2011-11-30436,154USD
At 2010-11-30321,030USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2011-11-30124,982USD
At 2010-11-30142,379USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2010-12-01 to 2011-11-30-4,769,836USD365
2009-12-01 to 2010-11-30-5,644,723USD365
2009-01-01 to 2009-11-30-2,566,226USD334

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2010-12-01 to 2011-11-30227,456USD365
2009-12-01 to 2010-11-30242,778USD365
2009-01-01 to 2009-11-30344,768USD334

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2010-12-01 to 2011-11-301,764USD365
2009-12-01 to 2010-11-30-3,808USD365
2009-01-01 to 2009-11-30-12,042USD334

Inspect the source

Entity
INTELLIPHARMACEUTICS INTERNATIONAL INC. / CIK 0001474835
Captured
SEC response SHA-256
b43bbafa3486320e53e47da45874c043f53139ec0b74aaba3fa200c8a1927667

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001474835.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))